We thank J&J for their leadership as they announced new efforts to combat Alzheimer’s disease, specifically their vaccine trial. In taking on this tau antibody and a tau-targeting vaccine, J&J is bringing hope to those impacted by Alzheimer’s disease, and addressing the need for cutting-edge research by launching this exciting trial. We are grateful for their leadership in prioritizing the critical need to combat this cruel disease, and are staying tuned for what is needed next to ensure that this trial moves forward safely and swiftly.
It is thrilling to see that the strides made in recent years, specifically work in looking for biomarkers of disease progression, have allowed the leadership at J&J to have confidence in leading new studies such as this.
https://www.biospace.com/article/j-and-j-expects-up-to-6-percent-growth-next-year-with-20-plus-new-drugs-by-2030-/